Can This Patient Start Vyvanse?
Yes, this patient can start Vyvanse 20 mg, but only after careful cardiovascular risk stratification and with close monitoring, particularly of heart rate and blood pressure. The presence of stress-induced PVCs requires pre-treatment evaluation but does not automatically contraindicate stimulant therapy if structural heart disease is excluded.
Critical Pre-Treatment Requirements
Before initiating Vyvanse, you must:
- Obtain a baseline ECG to assess QT interval and rule out structural abnormalities 1
- Document baseline blood pressure and heart rate 2
- Verify the PVCs are truly benign (no underlying structural heart disease, cardiomyopathy, or ischemia) 1
- Assess PVC burden - if >10-20% of total beats, cardiac MRI should be considered to exclude PVC-induced cardiomyopathy 3
The 2017 AHA/ACC/HRS guidelines explicitly list stimulants including amphetamines as medications with potential to provoke or aggravate ventricular arrhythmias 1. This is not a contraindication, but it mandates careful evaluation.
Risk Assessment Framework
The PVC Concern
Stress-induced PVCs in isolation are generally benign, but stimulants can:
- Increase sympathetic tone and potentially increase PVC frequency
- Elevate heart rate (mean increase of 2.8-5.2 bpm with lisdexamfetamine) 2
- Rarely cause vasospastic events 4
Key decision point: If her PVCs are truly stress-related and infrequent (<10% burden), and she has no structural heart disease, the risk is manageable with monitoring 3, 5.
The Levothyroxine Interaction
The good news: There is no direct pharmacokinetic interaction between lisdexamfetamine and levothyroxine 6. However:
- Ensure her TSH is well-controlled (0.4-4.5 mIU/L) before starting Vyvanse
- Suboptimal thyroid control (TSH >4.5) is associated with increased blood pressure, which could compound stimulant effects 7
- Her current 50 mcg dose suggests mild hypothyroidism - verify recent TSH is in range
Cardiovascular Monitoring Protocol
Baseline Assessment
- ECG (check QT interval, look for structural abnormalities)
- Blood pressure and heart rate
- Recent TSH level (within 3 months)
- Consider 24-hour Holter monitor if PVC burden is unknown
Post-Initiation Monitoring
Based on FDA data, lisdexamfetamine causes 2:
- Pulse increases of 2.8-5.2 bpm (dose-dependent)
- Minimal blood pressure changes in healthy adults
- 3.3-8.5% of patients had pulse outliers (≥100 bpm)
Monitor weekly for the first month:
- Blood pressure and heart rate at each visit
- Symptom assessment (palpitations, chest pain, dizziness)
- If PVCs worsen or new symptoms develop, obtain repeat ECG
Red Flags to Stop Vyvanse Immediately
- New sustained tachycardia (resting HR >100 bpm)
- Significant increase in PVC frequency or symptoms
- New chest pain, syncope, or near-syncope
- Blood pressure consistently >140/90 mmHg
- QT prolongation on follow-up ECG
Practical Considerations
Starting dose of 20 mg is appropriate - this is lower than the typical starting dose of 30 mg, which provides an additional safety margin 8.
The psychotropic medication guideline notes that stimulants can provoke arrhythmias but does not list them as Class B* (highest risk) medications 9. This suggests the risk, while real, is manageable with appropriate monitoring.
Common pitfall: Don't assume all PVCs are benign. The 2017 guidelines emphasize that PVCs can indicate underlying structural disease, particularly in the context of hypertension or other cardiac risk factors 1. At age 50, ensure she has no undiagnosed coronary disease or cardiomyopathy.
Alternative Consideration
If cardiovascular concerns are significant after evaluation, consider non-stimulant ADHD medications (atomoxetine, guanfacine) as alternatives, though these have their own cardiovascular effects and may be less effective 10.
Bottom line: Proceed with Vyvanse 20 mg if structural heart disease is excluded and monitoring can be ensured. The combination of stable hypothyroidism on levothyroxine and stress-induced PVCs does not absolutely contraindicate stimulant therapy, but requires vigilance 1, 2.